Skip to Main Content
Table 2.

Study IMbrave150: efficacy results.

Atezolizumab-bevacizumabSorafenib
(N = 336)(N = 165)
OS 
 Number of deaths (%) 96 (29%) 65 (39%) 
 Median OS in months (95% CI) NE (NE–NE) 13.2 (10.4, NE) 
 HRa (95% CI), Pb 0.58 (0.42–0.79), 0.00062 
PFSc 
 Number of events (%) 197 (59%) 109 (66%) 
 Median PFS in months (95% CI) 6.8 (5.8–8.3) 4.3 (4.0–5.6) 
 HRa (95% CI), P 0.59 (0.47–0.76), <0.0001 
Overall response ratec,e(ORR), RECIST 1.1 
 Number of responders (%) (95% CI) 93 (28%), (23%–33%) 19 (12%), (7%–17%) 
Pd <0.0001 
 Complete responses, n (%) 22 (7%) 
 Partial responses, n (%) 71 (21%) 19 (12%) 
 Median duration of response, months (95% CI) NE (NE–NE) 6.3 (4.7, NE) 
 Range, months (1.3+–13.4+) (1.4+–9.1+) 
ORRc,e, mRECIST 
 Number of responders (%) (95% CI) 112 (33%), (28–39) 21 (13%), (8–19) 
P <0.0001 
 Complete responses, n (%) 37 (11%) 3 (1.8%) 
 Partial responses, n (%) 75 (22%) 18 (11%) 
 Median duration of response, months (95% CI) NE (NE–NE) 6.3 (4.9 NE) 
 Range, months (1.3+–13.4+) (1.4+–9.1+) 
Atezolizumab-bevacizumabSorafenib
(N = 336)(N = 165)
OS 
 Number of deaths (%) 96 (29%) 65 (39%) 
 Median OS in months (95% CI) NE (NE–NE) 13.2 (10.4, NE) 
 HRa (95% CI), Pb 0.58 (0.42–0.79), 0.00062 
PFSc 
 Number of events (%) 197 (59%) 109 (66%) 
 Median PFS in months (95% CI) 6.8 (5.8–8.3) 4.3 (4.0–5.6) 
 HRa (95% CI), P 0.59 (0.47–0.76), <0.0001 
Overall response ratec,e(ORR), RECIST 1.1 
 Number of responders (%) (95% CI) 93 (28%), (23%–33%) 19 (12%), (7%–17%) 
Pd <0.0001 
 Complete responses, n (%) 22 (7%) 
 Partial responses, n (%) 71 (21%) 19 (12%) 
 Median duration of response, months (95% CI) NE (NE–NE) 6.3 (4.7, NE) 
 Range, months (1.3+–13.4+) (1.4+–9.1+) 
ORRc,e, mRECIST 
 Number of responders (%) (95% CI) 112 (33%), (28–39) 21 (13%), (8–19) 
P <0.0001 
 Complete responses, n (%) 37 (11%) 3 (1.8%) 
 Partial responses, n (%) 75 (22%) 18 (11%) 
 Median duration of response, months (95% CI) NE (NE–NE) 6.3 (4.9 NE) 
 Range, months (1.3+–13.4+) (1.4+–9.1+) 

Note: RECIST 1.1, refs. 15, 16.

Abbreviations: N/A, not applicable; NE, not estimable.

aStratified by geographic region (Asia, excluding Japan vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (<400 vs. ≥400 ng/mL).

bOn the basis of two-sided stratified log-rank test; compared to significance level 0.004 (two-sided), based on 161/312 = 52% information using the OBF method.

cPer independent radiology review.

dOn the basis of two-sided Cochran–Mantel–Haenszel test.

eConfirmed responses, +, denotes a censored value.

Close Modal

or Create an Account

Close Modal
Close Modal